Rep. Dan Crenshaw

Maddy summaryThis bill extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines "advanced drug product" as a drug using genetically targeted technology to modulate gene function (e.g., suppress or activate genes). This change directly affects pharmaceutical companies developing these specific advanced therapies by granting them longer market exclusivity. The policy change modifies the Social Security Act to provide extended protection for these innovative drugs, allowing companies more time to recoup research and development costs.

Maddy summaryHR 1651 would nullify a specific Environmental Protection Agency (EPA) rule finalized on May 9, 2024. This rule established emissions standards for greenhouse gases from new, modified, and reconstructed fossil fuel power plants, set guidelines for existing plants, and repealed the previous "Affordable Clean Energy Rule." The bill would make this EPA rule unenforceable, directly affecting fossil fuel power plants by removing these federal emissions requirements. It does not create new regulations but cancels an existing EPA rule.

Maddy summaryHRES 166 is a non-binding House resolution expressing U.S. support for the Iranian people's desire for a democratic, secular, and nonnuclear republic. It condemns the Iranian regime's terrorism, regional proxy wars, internal suppression of ethnic and religious minorities, and human rights abuses - including executions and repression of women-led protests. The resolution calls for holding the regime accountable through sanctions, supports the Ten-Point Plan for Iran’s democratic transition, and urges protection for Iranian political refugees in Albania. It does not create new laws but affirms U.S. policy alignment with Iranian protesters' demands.

Maddy summaryThis bill awards a Congressional Gold Medal to the 761st Tank Battalion (known as the "Black Panthers"), the first predominantly Black armored unit in World War II's European Theater. It recognizes their combat service from 1944-1946, including key roles in the Battle of the Bulge and breaking the Siegfried Line, despite facing racial prejudice during and after the war. The medal will be displayed at the National Museum of African American History and Culture, with bronze duplicates available for sale to cover costs. The bill commemorates the battalion's 130,000 enemy casualties inflicted, 50% casualty rate, and their 1978 Presidential Unit Citation. It does not create new laws or affect current policies.

New Era of Preventing End-Stage Kidney Disease Act This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease. Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute.  The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations. Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease. Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.

Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.

Maddy summaryHR 1539, the Medical Device Electronic Labeling Act, allows medical device manufacturers to provide required product labeling exclusively through electronic means, rather than physical copies. This change directly affects device manufacturers, healthcare providers, and patients who access device information. Key provisions require that electronic labeling be readily accessible online, manufacturers must provide paper copies upon request without cost, and the physical device label must still include essential safety and usage information. The bill does not alter existing safety standards but updates how labeling is delivered, with the FDA retaining authority to issue additional requirements via Federal Register notices for specific devices.

Maddy summaryHR 1502 authorizes the creation of a Congressional Gold Medal to honor the volunteers and communities (primarily from Nebraska, Colorado, and Kansas) who supported the North Platte Canteen during World War II. The bill directs the Treasury Secretary to design and strike the medal, which will be presented to the individuals who contributed to the canteen’s operations and then permanently displayed at the Lincoln County Historical Museum in North Platte, Nebraska. It also permits the sale of bronze duplicates to cover production costs, with proceeds going to the U.S. Mint. This is a commemorative measure recognizing historical service, not a policy change affecting current laws or programs.

Maddy summaryThis bill prohibits U.S. government funds from being used to support organizations (both foreign and domestic) that provide, promote, or fund abortion services abroad, including referrals, counseling, or training related to abortions. It directly affects foreign NGOs, multilateral organizations, and domestic groups receiving U.S. aid if they perform or support such activities, even within programs funded by the U.S. government. The restriction includes all forms of financial support and co-location of abortion services with other funded programs, with exceptions only for abortions resulting from rape or incest, or when the mother's life is endangered. This policy change alters how U.S. foreign aid is allocated to ensure funds do not support abortion-related services.

Maddy summaryHR 1492 amends the Social Security Act to extend the negotiation period for standard drug manufacturers under the federal drug pricing program. Specifically, it changes the timeframe from 7 years to 11 years for small-molecule drugs (like traditional pills) to negotiate prices with the government, aligning it with the existing 12-year period for complex biologic drugs (like insulin or monoclonal antibodies). This adjustment directly affects pharmaceutical companies that produce small-molecule drugs, giving them a longer window to negotiate pricing terms. The bill makes this change effective as if it had been part of the 2022 law that established the program.